Trial to evaluate feasibility & safety of intramural injection of belzupacap sarotalocan in NMIBC

Dr. Lerner elaborates on the phase 1, open-label trial to evaluate feasibility and safety of intramural injection of belzupacap sarotalocan (AU-011) in non-muscle–invasive bladder cancer (NMIBC).